August 3rd, 2011

Podcast 127: Why QALYs matter

(5 votes, average: 3.80 out of 5)

This time we talk with Dr. Katia Noyes, first author on a study of the cost-effectiveness of disease-modifying drugs in multiple sclerosis. If you don’t treat MS, don’t think that the topic is irrelevant. Noyes brings the issues of cost-effectiveness and the dreaded QALY into focus for clinicians who see patients.

After all, medical costs will undoubtedly become centerpieces of political debate over the next year and beyond. We’d all be better off being able to evaluate the arguments made.

Comments are closed.

Clinical Conversations

About the Podcast

To subscribe: Subscribe on iTunes

To have your comment included in a future podcast, call 617-440-4374. Please leave your name, number, and the podcast ID number.